Grifols SA (GRFS)
6.405
+0.14
(+2.15%)
USD |
NASDAQ |
Apr 26, 14:57
Grifols Revenue (TTM): 7.210B for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 7.210B |
| September 30, 2023 | 6.857B |
| June 30, 2023 | 6.761B |
| December 31, 2022 | 6.577B |
| September 30, 2022 | 6.253B |
| June 30, 2022 | 6.261B |
| June 30, 2021 | 6.201B |
| March 31, 2021 | 6.096B |
| December 31, 2020 | 6.095B |
| September 30, 2020 | 6.041B |
| June 30, 2020 | 5.920B |
| March 31, 2020 | 5.819B |
| December 31, 2019 | 5.705B |
| September 30, 2019 | 5.594B |
| June 30, 2019 | 5.462B |
| March 31, 2019 | 5.349B |
| December 31, 2018 | 5.292B |
| September 30, 2018 | 5.154B |
| June 30, 2018 | 5.068B |
| March 31, 2018 | 5.002B |
| December 31, 2017 | 4.876B |
| September 30, 2017 | 4.803B |
| June 30, 2017 | 4.676B |
| March 31, 2017 | 4.553B |
| Date | Value |
|---|---|
| December 31, 2016 | 4.480B |
| September 30, 2016 | 4.458B |
| June 30, 2016 | 4.422B |
| March 31, 2016 | 4.396B |
| December 31, 2015 | 4.364B |
| September 30, 2015 | 4.346B |
| June 30, 2015 | 4.363B |
| March 31, 2015 | 4.382B |
| December 31, 2014 | 4.450B |
| September 30, 2014 | 4.251B |
| June 30, 2014 | 4.037B |
| March 31, 2014 | 3.833B |
| December 31, 2013 | 3.642B |
| September 30, 2013 | 3.554B |
| June 30, 2013 | 3.475B |
| March 31, 2013 | 3.399B |
| December 31, 2012 | 3.370B |
| September 30, 2012 | 3.307B |
| June 30, 2012 | 3.310B |
| March 31, 2012 | 3.014B |
| December 31, 2011 | 2.497B |
| September 30, 2011 | 2.044B |
| June 30, 2011 | 1.488B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
5.462B
Minimum
Jun 2019
7.210B
Maximum
Dec 2023
6.190B
Average
6.096B
Median
Mar 2021
Revenue (TTM) Benchmarks
| DBV Technologies SA | -- |
| Adaptimmune Therapeutics PLC | 60.28M |
| Biodexa Pharmaceuticals Plc | 0.4761M |
| NuCana PLC | -- |
| Autolus Therapeutics PLC | -- |